Newman Dignan & Sheerar Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,936 shares of the medical research company’s stock after selling 135 shares during the period. Newman Dignan & Sheerar Inc.’s holdings in Thermo Fisher Scientific were worth $804,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. CX Institutional bought a new position in Thermo Fisher Scientific during the first quarter valued at $36,000. Freestone Capital Holdings LLC increased its position in Thermo Fisher Scientific by 46.1% during the fourth quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock valued at $2,256,000 after acquiring an additional 3,180 shares during the last quarter. Putnam FL Investment Management Co. increased its position in Thermo Fisher Scientific by 2.9% during the fourth quarter. Putnam FL Investment Management Co. now owns 29,001 shares of the medical research company’s stock valued at $6,490,000 after acquiring an additional 810 shares during the last quarter. Calamos Advisors LLC increased its position in Thermo Fisher Scientific by 5.4% during the fourth quarter. Calamos Advisors LLC now owns 132,462 shares of the medical research company’s stock valued at $29,644,000 after acquiring an additional 6,769 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Handelsbanken Fonder AB now owns 367,354 shares of the medical research company’s stock valued at $82,210,000 after acquiring an additional 14,789 shares during the last quarter. Institutional investors own 88.66% of the company’s stock.

A number of research analysts have weighed in on TMO shares. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, January 3rd. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, January 5th. Deutsche Bank boosted their price objective on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $270.00 to $288.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $289.00.

In related news, SVP Gregory J. Herrema sold 19,808 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $253.29, for a total value of $5,017,168.32. Following the completion of the sale, the senior vice president now directly owns 25,688 shares of the company’s stock, valued at $6,506,513.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Gregory J. Herrema sold 5,400 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the completion of the sale, the senior vice president now directly owns 31,846 shares of the company’s stock, valued at $8,009,587.46. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,927 shares of company stock valued at $9,388,124. 0.49% of the stock is owned by insiders.

NYSE:TMO opened at $278.85 on Thursday. Thermo Fisher Scientific Inc. has a 1-year low of $202.83 and a 1-year high of $280.11. The stock has a market capitalization of $110.84 billion, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 1.83 and a beta of 1.13. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. During the same period in the prior year, the firm earned $2.79 earnings per share. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 16th. Investors of record on Friday, March 15th will be paid a $0.19 dividend. The ex-dividend date is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 6.83%.

COPYRIGHT VIOLATION NOTICE: “Newman Dignan & Sheerar Inc. Trims Position in Thermo Fisher Scientific Inc. (TMO)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2019/04/11/newman-dignan-sheerar-inc-trims-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.